Drug Trial Radar · NCT06868732
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
288
Planned (sponsor's estimate)
Start
Apr 2, 2025
Primary completion
Jun 30, 2028
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase Ib clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016 in combination therapy. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.
Conditions
- Advanced Non-small Cell Lung Cancer
Interventions
JSKN016Drug
Administered intravenously according to protocol.
CarboplatinDrug
AUC 5, Q3W, administered intravenously according to protocol.
Furmonertinib MesylateDrug
160mg(cohort1A-b)or 80mg(cohort 5), qd, administered according to protocol.
IvonescimabDrug
20mg/kg, Q3W, administered intravenously according to protocol.
DocetaxelDrug
60mg/m\^2, Q3W, administered intravenously according to protocol.
TislelizumabDrug
200mg, Q3W, administered intravenously according to protocol.
PembrolizumabDrug
200mg, Q3W, administered intravenously according to protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR assessed by the investigator per RECIST v1.1Time frame: Up to 24months
- Safety reflected by AETime frame: Up to 24months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.